<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930214</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0002-P</org_study_id>
    <nct_id>NCT01930214</nct_id>
  </id_info>
  <brief_title>Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)</brief_title>
  <acronym>MACE</acronym>
  <official_title>Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Systems Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The two objectives of the study are to assess the current standard of care treatment outcome
      in none/mild, moderate and severe calcified coronary lesions and to obtain financial data
      and procedure data to support reimbursement initiatives and health care economics analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, non-randomized, multi-center study includes subjects who meet all of the
      inclusion and none of the exclusion criteria and sign the ICF.  This study may treat up to
      approximately 500 subjects at up to 50 active sites in the U.S.  Subjects will be followed
      up to three (3) years.  Subjects will be stratified into one (1) of three (3) arms based on
      the degree of calcification in the coronary lesion as defined by this protocol. An interim
      analysis of standard of care treatment used will be performed after an arm has 40 subjects
      whom have completed the discharge visit. The duration of the study is expected to be
      approximately four (4) years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To assess the current standard of care treatment outcome in none/mild, moderate and severe calcified coronary lesions using a composite of MACE.</measure>
    <time_frame>30-day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety of the current standard of care treatment when used to facilitate stent deployment in de novo coronary lesions. This will be measured by a composite of MACE at 30-day post index procedure.  TVR will be determined by the Angiographic Core Laboratory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Assess the current standard of care traetment outcome in none/mild, moderate and severe calcified coronary lesions using a composite of MACE.</measure>
    <time_frame>one (1) year post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety of the current standard of care treatment when used to facilitate stent deployment in de novo coronary lesions. This will be measured by a composite of MACE rate at one (1) year post index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the current standard of care treatment outcome in non/mil, moderate and severe calcified coronary lesions using procedural and lesion success.</measure>
    <time_frame>Procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the current standard of care treatment capability of successfully facilitating stent deployment in de novo coronary lesions.  Procedural success is defined as success in  facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE, coronary lesion as determined by the Angiographic Core Laboratory. Lesion success is defined as success in facilitating stent delivery with a post-procedural result of &lt;50% residual stenosis for a given lesion treated during index procedure without severe angiographic complications determined by the Angiographic Core Laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of health care costs associated with percutaneous coronary revascularization according to the level of lesion calcification.</measure>
    <time_frame>Procedure, one (1) year and three (3) year follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heath care resource utilization, including hospital billing data (e.g., UB-04 forms, itemized bills) from the index hospitalization and any subsequent coronary revascularization procedures will be collected  by the Health Economics Core Laboratory. These data will be used to characterize the health care costs associated with percutaneous coronary revascularization according to the level of lesion calcification and to support other secondary economic comparisons.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Calcification in Coronary Lesions</condition>
  <arm_group>
    <arm_group_label>None/mild calcification</arm_group_label>
    <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis, or
Presence of ≤180° of calcium at one (1) cross section.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Calcification</arm_group_label>
    <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion, or
Presence of 181° to 269° of calcium at one (1)  cross section.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe calcification</arm_group_label>
    <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion, or
Presence of ≥270° of calcium at one (1) cross section.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        18 years or older who are scheduled for percutaneous coronary revascularization involving
        stent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be at least 18 years of age.

          2. Subjects must be scheduled for percutaneous coronary revascularization involving
             stent deployment in de novo coronary lesions.   Percutaneous coronary
             revascularization is defined as treatment with commercially available devices that
             may include but not limited to balloon angioplasty, cutting balloon, rotablation,
             etc. followed by the stent placement.

          3. Subjects CK-MB must be less than or equal to the upper limit of lab normal value
             within eight (8) hours prior to procedure.  If CK-MB results are not yet available
             prior to initiating procedure, subjects Troponin I or Troponin T must be less than or
             equal to the upper limit of lab normal value within eight (8) hours prior to the
             procedure.

          4. The target lesion must be a de novo coronary lesion that has not been previously
             treated with any interventional procedure.

          5. The target vessel must be a native coronary artery with:

               1. A stenosis ≥ 70% and &lt; 100%, or

               2. A stenosis ≥ 50% &lt; 70% with evidence of clinical ischemia as demonstrated by
                  either:

             i. Positive stress test, or ii. Fractional Flow Reserve (FFR) value ≤ 0.8, or iii.
             IVUS minimum lumen area (MLA) ≤ 4.0 mm2

          6. The target vessel reference diameter must be ≥ 2.5mm and ≤  4.0 mm.

          7. The lesion length must not exceed 40 mm.

          8. The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow three
             (3) at baseline.

        Exclusion Criteria:

          1. Inability to understand the study or a history of non-compliance with medical advice.

          2. Unwilling or unable to sign the MACE clinical study ICF.

          3. History of any cognitive or mental health status that would interfere with study
             participation.

          4. Currently enrolled in any other pre-approval investigational study.  This does not
             apply to long-term post-market studies unless these studies might clinically
             interfere with the current study endpoints (e.g., limit use of study-required
             medication, etc.).

          5. Female subjects who are pregnant or planning to become pregnant within the study
             period.

          6. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or
             clopidogrel without adequate alternative medications.

          7. Known sensitivity to contrast media, which cannot be adequately pre-medicated.

          8. Diagnosed with chronic renal failure unless under hemodialysis, or has a serum
             creatinine level &gt;2.5 mg/dl.

          9. History of major cardiac intervention within 30-day, not including a PCI procedure
             for a staging purpose.

         10. Evidence of heart failure within the last 6 months by either:

             i. Left Ventricualr Ejection Fraction (LVEF) ≤ 25%, or ii. New York Heart Association
             (NYHA) class III or IV, or iii. Clinical symptoms

         11. History of a stroke or transient ischemic attack (TIA) within six (6) months

         12. Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months.

         13. History of bleeding diathesis or coagulopathy or intention to refuse blood
             transfusion if one should become necessary.

         14. Concurrent medical condition with a life expectancy of &lt; 36 months.

         15. History of immune deficiency.

         16. Uncontrolled insulin dependent diabetes.

         17. Evidence of active infections on the day of the index procedure.

         18. Subject has planned cardiovascular intervention within 60 days post index procedure.

         19. Subject with angiographically confirmed evidence of more than two (2) lesions within
             one (1) vessel or more than one (1) vessel requiring intervention, unless the
             treatment is staged.  See Section 10.1 for more details.

         20. Target lesion is located in a native vessel distal to anastomosis with a saphenous
             vein graft or Left Internal Mammary Artery/ Right Internal Mammary Artery (LIMA/RIMA)
             bypass.

         21. Target vessel has angiographically visible or suspected thrombus.

         22. Target vessel appears to be/is excessively tortuous at baseline.

         23. Target lesion is an ostial location (within 5mm of ostium) or an unprotected left
             main lesion.

         24. Target lesion is a bifurcation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samin K Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Kleine</last_name>
    <phone>651-259-2840</phone>
    <email>jkleine@csi360.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Kumar</last_name>
    <phone>651-259-1621</phone>
    <email>kkumar@csi360.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Mego, MD</last_name>
      <phone>501-664-5860</phone>
      <email>david.mego@arheart.com</email>
    </contact>
    <contact_backup>
      <last_name>Brandy Griffin</last_name>
      <phone>501-978-3702</phone>
      <email>brandy.griffin@arheart.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Mego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Balian, MD</last_name>
      <phone>818-243-9600</phone>
      <email>Md4hart@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Lily Villalobos</last_name>
      <phone>818-409-8464</phone>
      <email>lily.villalobos@ah.org</email>
    </contact_backup>
    <investigator>
      <last_name>Harry Balian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talhat Azemi, MD</last_name>
      <phone>860-545-2975</phone>
      <email>tazemi@harthosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Katten</last_name>
      <phone>860-545-1537</phone>
      <email>Deborah.Katten@hhchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Talhat Azemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Medical Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Ebersole, MD</last_name>
      <phone>863-904-2482</phone>
      <email>DEbersole@watsonclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Noreen McGowan</last_name>
      <phone>863-904-2482</phone>
      <email>nmcgowan@watsonclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas Ebersole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center Heart Institute</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirat Beohar, MD</last_name>
      <phone>305-674-2754</phone>
      <email>Nirat.beohar@msmc.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Mon</last_name>
      <phone>305-674-2169</phone>
      <email>Ana.mon@msmc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nirat Beohar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Resar, MD</last_name>
      <phone>410-614-1132</phone>
      <email>jresar@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Audrey Dudek</last_name>
      <phone>410-955-6839</phone>
      <email>adudek1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Resar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Maryland</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donald Cutlip, MD</last_name>
      <phone>617-667-8800</phone>
      <email>dcutlip@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenifer Kaufman</last_name>
      <phone>617-632-8956</phone>
      <email>jmkaufma@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Cutlip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Bay Regional</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Lee, MD</last_name>
      <phone>989-894-3278</phone>
      <email>Daniel.lee1965@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Colette Quart</last_name>
      <phone>989-894-3290</phone>
      <email>Colette.Quart@mclaren.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boone Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjeev Ravipudi, MD</last_name>
      <phone>573-256-7700</phone>
      <email>sravipudi@moheartcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Melegrito</last_name>
      <phone>573-256-3046</phone>
      <email>kellym@moheartcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeev Ravipudi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Barth, MD</last_name>
      <phone>816-931-1883</phone>
      <email>cbarth@saint-lukes.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Seifert</last_name>
      <phone>816-932-9862</phone>
      <email>lseifert@saint-lukes.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Barth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lasala, MD</last_name>
      <phone>314-362-3729</phone>
      <email>jlasala@dom.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Holly Wiesehan</last_name>
      <phone>314-362-1986</phone>
      <email>hwieseha@dom.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Lasala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virender Sethi, MD</last_name>
      <phone>551-996-2744</phone>
      <email>vsethi@hackensackUMC.org</email>
    </contact>
    <contact_backup>
      <last_name>Jana Tancredi</last_name>
      <phone>551-996-2353</phone>
      <email>jtancredi@hackensackUMC.org</email>
    </contact_backup>
    <investigator>
      <last_name>Virender Sethi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jersey Shore Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Abbud, MD</last_name>
      <phone>732-663-1123</phone>
      <email>ziadabbud@optonline.net</email>
    </contact>
    <contact_backup>
      <last_name>Linda Murphy</last_name>
      <phone>732776-4796</phone>
      <email>lMurphy@meridianhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ziad Abbud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai New York</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samin Sharma, MD</last_name>
      <email>samin.sharma@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Omarys Herasme</last_name>
      <phone>212-241-3282</phone>
      <email>omarys.herasme@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samin Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Elizabeth Medical Center</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Sassower, MD</last_name>
      <phone>315-733-7598</phone>
      <email>masmdfacc@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Passacantando</last_name>
      <phone>315-235-7476</phone>
      <email>mpassacantando@stemc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sassower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DukeUniversity Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manesh Patel, MD</last_name>
      <phone>919-668-8917</phone>
      <email>Manesh.patel@dm.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Hamil</last_name>
      <phone>919-681-4680</phone>
      <email>Jennifer.hamill@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Manesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Carolina Heart &amp; Vascular Specialists</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Adams, MD</last_name>
      <phone>919-787-5380</phone>
      <email>George.adams@rexhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Matthews</last_name>
      <phone>919-231-8253</phone>
      <phone_ext>4001</phone_ext>
      <email>dmatthews@wakeheartresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John Health System</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaurav Kumar, MD</last_name>
      <phone>918-744-3426</phone>
      <email>Gaurav.kumar@sjmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Candida Barlow</last_name>
      <phone>918-744-2685</phone>
      <email>Candida.Barlow@sjmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Gaurav Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Yoho, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sherie Macht, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jason Yoho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
